Tipping the balance: toward rational combination therapies to overcome venetoclax resistance in mantle cell lymphoma View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2022-06-20

AUTHORS

Yvonne J. Thus, Eric Eldering, Arnon P. Kater, Marcel Spaargaren

ABSTRACT

Mantle cell lymphoma (MCL), an aggressive, but incurable B-cell lymphoma, is genetically characterized by the t(11;14) translocation, resulting in the overexpression of Cyclin D1. In addition, deregulation of the B-cell lymphoma-2 (BCL-2) family proteins BCL-2, B-cell lymphoma-extra large (BCL-XL), and myeloid cell leukemia-1 (MCL-1) is highly common in MCL. This renders these BCL-2 family members attractive targets for therapy; indeed, the BCL-2 inhibitor venetoclax (ABT-199), which already received FDA approval for the treatment of chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML), shows promising results in early clinical trials for MCL. However, a significant subset of patients show primary resistance or will develop resistance upon prolonged treatment. Here, we describe the underlying mechanisms of venetoclax resistance in MCL, such as upregulation of BCL-XL or MCL-1, and the recent (clinical) progress in the development of inhibitors for these BCL-2 family members, followed by the transcriptional and (post-)translational (dys)regulation of the BCL-2 family proteins, including the role of the lymphoid organ microenvironment. Based upon these insights, we discuss how rational combinations of venetoclax with other therapies can be exploited to prevent or overcome venetoclax resistance and improve MCL patient outcome. More... »

PAGES

2165-2176

References to SciGraph publications

  • 2021-01-25. Regulation of Bcl-XL by non-canonical NF-κB in the context of CD40-induced drug resistance in CLL in CELL DEATH & DIFFERENTIATION
  • 2017-02-13. Macrophages confer survival signals via CCR1-dependent translational MCL-1 induction in chronic lymphocytic leukemia in ONCOGENE
  • 2013-12-12. Guilty bystanders: nurse-like cells as a model of microenvironmental support for leukemic lymphocytes in CLINICAL AND EXPERIMENTAL MEDICINE
  • 2016-05-09. FBXO10 deficiency and BTK activation upregulate BCL2 expression in mantle cell lymphoma in ONCOGENE
  • 2020-12-14. Targeting eIF4F translation initiation complex with SBI-756 sensitises B lymphoma cells to venetoclax in BRITISH JOURNAL OF CANCER
  • 2011-02-04. Sorafenib induces cell death in chronic lymphocytic leukemia by translational downregulation of Mcl-1 in LEUKEMIA
  • 2011-03-25. Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway in LEUKEMIA
  • 2020-06-26. Identification of the SRC-family tyrosine kinase HCK as a therapeutic target in mantle cell lymphoma in LEUKEMIA
  • 2020-11-02. Targeting BCL-2 in B-cell malignancies and overcoming therapeutic resistance in CELL DEATH & DISEASE
  • 2021-10-18. The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs in NATURE REVIEWS CANCER
  • 2018-02-06. Targeting the IL-6/JAK/STAT3 signalling axis in cancer in NATURE REVIEWS CLINICAL ONCOLOGY
  • 2019-12-11. A novel CDK9 inhibitor increases the efficacy of venetoclax (ABT-199) in multiple models of hematologic malignancies in LEUKEMIA
  • 2021-10-30. Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study in JOURNAL OF HEMATOLOGY & ONCOLOGY
  • 2018-11-19. Dynamic molecular monitoring reveals that SWI–SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma in NATURE MEDICINE
  • 2020-09-17. BCMA-targeted immunotherapy for multiple myeloma in JOURNAL OF HEMATOLOGY & ONCOLOGY
  • 2018-02-20. Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia in NATURE COMMUNICATIONS
  • 2022-02-24. Aberrantly expressed Wnt5a in nurse-like cells drives resistance to Venetoclax in chronic lymphocytic leukemia in CELL DEATH DISCOVERY
  • 2017-06-30. BET protein proteolysis targeting chimera (PROTAC) exerts potent lethal activity against mantle cell lymphoma cells in LEUKEMIA
  • 2021-08-31. Venetoclax-resistant CLL cells show a highly activated and proliferative phenotype in CANCER IMMUNOLOGY, IMMUNOTHERAPY
  • 2022-04-05. Cyclin-dependent kinase inhibitor fadraciclib (CYC065) depletes anti-apoptotic protein and synergizes with venetoclax in primary chronic lymphocytic leukemia cells in LEUKEMIA
  • 2017-01-23. Bruton’s tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia in LEUKEMIA
  • 2017-11-17. How does p53 induce apoptosis and how does this relate to p53-mediated tumour suppression? in CELL DEATH & DIFFERENTIATION
  • 2020-06-23. ERK signalling: a master regulator of cell behaviour, life and fate in NATURE REVIEWS MOLECULAR CELL BIOLOGY
  • 2021-11-12. Apoptotic stress-induced FGF signalling promotes non-cell autonomous resistance to cell death in NATURE COMMUNICATIONS
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1038/s41375-022-01627-9

    DOI

    http://dx.doi.org/10.1038/s41375-022-01627-9

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1148806066

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/35725771


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Oncology and Carcinogenesis", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Adult", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Antineoplastic Agents", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Bridged Bicyclo Compounds, Heterocyclic", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Cell Line, Tumor", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Drug Resistance, Neoplasm", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Lymphoma, B-Cell", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Lymphoma, Mantle-Cell", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Myeloid Cell Leukemia Sequence 1 Protein", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Proto-Oncogene Proteins c-bcl-2", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Sulfonamides", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Tumor Microenvironment", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "bcl-X Protein", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Cancer Center Amsterdam (CCA), Cancer Biology and Immunology, Target & Therapy Discovery, Amsterdam, The Netherlands", 
              "id": "http://www.grid.ac/institutes/grid.16872.3a", 
              "name": [
                "Department of Pathology, Amsterdam UMC location University of Amsterdam, Amsterdam, The Netherlands", 
                "Lymphoma and Myeloma Center Amsterdam (LYMMCARE), Amsterdam, The Netherlands", 
                "Cancer Center Amsterdam (CCA), Cancer Biology and Immunology, Target & Therapy Discovery, Amsterdam, The Netherlands"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Thus", 
            "givenName": "Yvonne J.", 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Amsterdam Institute for Infection and Immunity, Cancer Immunology, Amsterdam, The Netherlands", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "Lymphoma and Myeloma Center Amsterdam (LYMMCARE), Amsterdam, The Netherlands", 
                "Cancer Center Amsterdam (CCA), Cancer Biology and Immunology, Target & Therapy Discovery, Amsterdam, The Netherlands", 
                "Department of Experimental Immunology, Amsterdam UMC location University of Amsterdam, Amsterdam, The Netherlands", 
                "Amsterdam Institute for Infection and Immunity, Cancer Immunology, Amsterdam, The Netherlands"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Eldering", 
            "givenName": "Eric", 
            "id": "sg:person.01324263263.24", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01324263263.24"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Hematology, Amsterdam UMC location University of Amsterdam, Amsterdam, The Netherlands", 
              "id": "http://www.grid.ac/institutes/grid.7177.6", 
              "name": [
                "Lymphoma and Myeloma Center Amsterdam (LYMMCARE), Amsterdam, The Netherlands", 
                "Cancer Center Amsterdam (CCA), Cancer Biology and Immunology, Target & Therapy Discovery, Amsterdam, The Netherlands", 
                "Department of Hematology, Amsterdam UMC location University of Amsterdam, Amsterdam, The Netherlands"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Kater", 
            "givenName": "Arnon P.", 
            "id": "sg:person.01052273406.90", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01052273406.90"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Cancer Center Amsterdam (CCA), Cancer Biology and Immunology, Target & Therapy Discovery, Amsterdam, The Netherlands", 
              "id": "http://www.grid.ac/institutes/grid.16872.3a", 
              "name": [
                "Department of Pathology, Amsterdam UMC location University of Amsterdam, Amsterdam, The Netherlands", 
                "Lymphoma and Myeloma Center Amsterdam (LYMMCARE), Amsterdam, The Netherlands", 
                "Cancer Center Amsterdam (CCA), Cancer Biology and Immunology, Target & Therapy Discovery, Amsterdam, The Netherlands"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Spaargaren", 
            "givenName": "Marcel", 
            "id": "sg:person.0724422422.86", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0724422422.86"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1038/s41568-021-00407-4", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1141956814", 
              "https://doi.org/10.1038/s41568-021-00407-4"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/cdd.2017.169", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1092746764", 
              "https://doi.org/10.1038/cdd.2017.169"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/leu.2011.2", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1028195451", 
              "https://doi.org/10.1038/leu.2011.2"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/s41591-018-0243-z", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1109946036", 
              "https://doi.org/10.1038/s41591-018-0243-z"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/s41375-019-0652-0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1123262577", 
              "https://doi.org/10.1038/s41375-019-0652-0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/s41416-020-01205-9", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1133486790", 
              "https://doi.org/10.1038/s41416-020-01205-9"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00262-021-03043-x", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1140776702", 
              "https://doi.org/10.1007/s00262-021-03043-x"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/s41580-020-0255-7", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1128679372", 
              "https://doi.org/10.1038/s41580-020-0255-7"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/leu.2011.46", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1033286363", 
              "https://doi.org/10.1038/leu.2011.46"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/leu.2017.207", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1090318815", 
              "https://doi.org/10.1038/leu.2017.207"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/s41418-020-00692-w", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1134846320", 
              "https://doi.org/10.1038/s41418-020-00692-w"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/s41467-021-26613-0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1142539803", 
              "https://doi.org/10.1038/s41467-021-26613-0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/onc.2016.155", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1007392184", 
              "https://doi.org/10.1038/onc.2016.155"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/s41375-020-0934-6", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1128770760", 
              "https://doi.org/10.1038/s41375-020-0934-6"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/onc.2016.515", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1083804989", 
              "https://doi.org/10.1038/onc.2016.515"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/leu.2017.32", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1074210574", 
              "https://doi.org/10.1038/leu.2017.32"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/s41420-022-00884-y", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1145815027", 
              "https://doi.org/10.1038/s41420-022-00884-y"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/s41419-020-03144-y", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1132250737", 
              "https://doi.org/10.1038/s41419-020-03144-y"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/s41375-022-01553-w", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1146886772", 
              "https://doi.org/10.1038/s41375-022-01553-w"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/s41467-018-03170-7", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1101045812", 
              "https://doi.org/10.1038/s41467-018-03170-7"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/s13045-020-00962-7", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1130921904", 
              "https://doi.org/10.1186/s13045-020-00962-7"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nrclinonc.2018.8", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1100835036", 
              "https://doi.org/10.1038/nrclinonc.2018.8"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s10238-013-0268-z", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1028736156", 
              "https://doi.org/10.1007/s10238-013-0268-z"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/s13045-021-01188-x", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1142273846", 
              "https://doi.org/10.1186/s13045-021-01188-x"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2022-06-20", 
        "datePublishedReg": "2022-06-20", 
        "description": "Mantle cell lymphoma (MCL), an aggressive, but incurable B-cell lymphoma, is genetically characterized by the t(11;14) translocation, resulting in the overexpression of Cyclin D1. In addition, deregulation of the B-cell lymphoma-2 (BCL-2) family proteins BCL-2, B-cell lymphoma-extra large (BCL-XL), and myeloid cell leukemia-1 (MCL-1) is highly common in MCL. This renders these BCL-2 family members attractive targets for therapy; indeed, the BCL-2 inhibitor venetoclax (ABT-199), which already received FDA approval for the treatment of chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML), shows promising results in early clinical trials for MCL. However, a significant subset of patients show primary resistance or will develop resistance upon prolonged treatment. Here, we describe the underlying mechanisms of venetoclax resistance in MCL, such as upregulation of BCL-XL or MCL-1, and the recent (clinical) progress in the development of inhibitors for these BCL-2 family members, followed by the transcriptional and (post-)translational (dys)regulation of the BCL-2 family proteins, including the role of the lymphoid organ microenvironment. Based upon these insights, we discuss how rational combinations of venetoclax with other therapies can be exploited to prevent or overcome venetoclax resistance and improve MCL patient outcome.", 
        "genre": "article", 
        "id": "sg:pub.10.1038/s41375-022-01627-9", 
        "isAccessibleForFree": true, 
        "isPartOf": [
          {
            "id": "sg:journal.1097065", 
            "issn": [
              "0887-6924", 
              "1476-5551"
            ], 
            "name": "Leukemia", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "9", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "36"
          }
        ], 
        "keywords": [
          "mantle cell lymphoma", 
          "acute myeloid leukemia", 
          "chronic lymphocytic leukemia", 
          "myeloid cell leukemia-1", 
          "venetoclax resistance", 
          "cell lymphoma", 
          "BCL-2 inhibitor venetoclax", 
          "incurable B-cell lymphoma", 
          "early clinical trials", 
          "B-cell lymphoma", 
          "rational combination therapies", 
          "combination therapy", 
          "clinical trials", 
          "patient outcomes", 
          "primary resistance", 
          "inhibitor venetoclax", 
          "myeloid leukemia", 
          "lymphocytic leukemia", 
          "B cells", 
          "FDA approval", 
          "cyclin D1", 
          "lymphoma", 
          "therapy", 
          "B-cell lymphoma-2 (Bcl-2) family", 
          "organ microenvironment", 
          "development of inhibitors", 
          "Bcl-2", 
          "venetoclax", 
          "significant subset", 
          "leukemia", 
          "attractive target", 
          "family members", 
          "Bcl-xL", 
          "treatment", 
          "Bcl-2 family members", 
          "rational combination", 
          "Bcl-2 family proteins", 
          "patients", 
          "trials", 
          "upregulation", 
          "promising results", 
          "outcomes", 
          "resistance", 
          "inhibitors", 
          "D1", 
          "approval", 
          "microenvironment", 
          "overexpression", 
          "family proteins", 
          "subset", 
          "translocation", 
          "target", 
          "protein", 
          "role", 
          "deregulation", 
          "mechanism", 
          "family", 
          "combination", 
          "addition", 
          "recent progress", 
          "members", 
          "development", 
          "balance", 
          "progress", 
          "results", 
          "insights"
        ], 
        "name": "Tipping the balance: toward rational combination therapies to overcome venetoclax resistance in mantle cell lymphoma", 
        "pagination": "2165-2176", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1148806066"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1038/s41375-022-01627-9"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "35725771"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1038/s41375-022-01627-9", 
          "https://app.dimensions.ai/details/publication/pub.1148806066"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-10-01T06:50", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20221001/entities/gbq_results/article/article_926.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1038/s41375-022-01627-9"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/s41375-022-01627-9'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/s41375-022-01627-9'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/s41375-022-01627-9'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/s41375-022-01627-9'


     

    This table displays all metadata directly associated to this object as RDF triples.

    308 TRIPLES      21 PREDICATES      128 URIs      96 LITERALS      20 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1038/s41375-022-01627-9 schema:about N11d8c0c223ac43afa6fac0c709ac101e
    2 N29fdcf1fb4594d76a60f8d68c5d2ccc6
    3 N332a0ba1f761446a871e99b27eb1eb88
    4 N368ca20fd3794f6693a02ee344c05fde
    5 N5845b7ef0e8e4e97939f7d4faf837737
    6 N6e23007ee6d541c397b0b769c5e8e62b
    7 N703a33a2c76f441aaf0ab30d64a26466
    8 N75f603c3f1b24743a1209d3b504cfd6b
    9 N76f3a49494a74495ae12044ce4683486
    10 N77163c080ce84af185a6b2681678ce49
    11 N7ea667fc86014dc7996a8e33e74b5cd1
    12 N8ff5a58c5e7a47f794511ba901c83e13
    13 N9d932d5e0192425eb5a7a05ea299eb53
    14 anzsrc-for:11
    15 anzsrc-for:1112
    16 schema:author Nc3feb40582d04ae49e58b9f2f6e9c549
    17 schema:citation sg:pub.10.1007/s00262-021-03043-x
    18 sg:pub.10.1007/s10238-013-0268-z
    19 sg:pub.10.1038/cdd.2017.169
    20 sg:pub.10.1038/leu.2011.2
    21 sg:pub.10.1038/leu.2011.46
    22 sg:pub.10.1038/leu.2017.207
    23 sg:pub.10.1038/leu.2017.32
    24 sg:pub.10.1038/nrclinonc.2018.8
    25 sg:pub.10.1038/onc.2016.155
    26 sg:pub.10.1038/onc.2016.515
    27 sg:pub.10.1038/s41375-019-0652-0
    28 sg:pub.10.1038/s41375-020-0934-6
    29 sg:pub.10.1038/s41375-022-01553-w
    30 sg:pub.10.1038/s41416-020-01205-9
    31 sg:pub.10.1038/s41418-020-00692-w
    32 sg:pub.10.1038/s41419-020-03144-y
    33 sg:pub.10.1038/s41420-022-00884-y
    34 sg:pub.10.1038/s41467-018-03170-7
    35 sg:pub.10.1038/s41467-021-26613-0
    36 sg:pub.10.1038/s41568-021-00407-4
    37 sg:pub.10.1038/s41580-020-0255-7
    38 sg:pub.10.1038/s41591-018-0243-z
    39 sg:pub.10.1186/s13045-020-00962-7
    40 sg:pub.10.1186/s13045-021-01188-x
    41 schema:datePublished 2022-06-20
    42 schema:datePublishedReg 2022-06-20
    43 schema:description Mantle cell lymphoma (MCL), an aggressive, but incurable B-cell lymphoma, is genetically characterized by the t(11;14) translocation, resulting in the overexpression of Cyclin D1. In addition, deregulation of the B-cell lymphoma-2 (BCL-2) family proteins BCL-2, B-cell lymphoma-extra large (BCL-XL), and myeloid cell leukemia-1 (MCL-1) is highly common in MCL. This renders these BCL-2 family members attractive targets for therapy; indeed, the BCL-2 inhibitor venetoclax (ABT-199), which already received FDA approval for the treatment of chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML), shows promising results in early clinical trials for MCL. However, a significant subset of patients show primary resistance or will develop resistance upon prolonged treatment. Here, we describe the underlying mechanisms of venetoclax resistance in MCL, such as upregulation of BCL-XL or MCL-1, and the recent (clinical) progress in the development of inhibitors for these BCL-2 family members, followed by the transcriptional and (post-)translational (dys)regulation of the BCL-2 family proteins, including the role of the lymphoid organ microenvironment. Based upon these insights, we discuss how rational combinations of venetoclax with other therapies can be exploited to prevent or overcome venetoclax resistance and improve MCL patient outcome.
    44 schema:genre article
    45 schema:isAccessibleForFree true
    46 schema:isPartOf N009b8836782141e9b60faf5a5a503e9c
    47 N767d659cec51411a8b7f2f6276dbd196
    48 sg:journal.1097065
    49 schema:keywords B cells
    50 B-cell lymphoma
    51 B-cell lymphoma-2 (Bcl-2) family
    52 BCL-2 inhibitor venetoclax
    53 Bcl-2
    54 Bcl-2 family members
    55 Bcl-2 family proteins
    56 Bcl-xL
    57 D1
    58 FDA approval
    59 acute myeloid leukemia
    60 addition
    61 approval
    62 attractive target
    63 balance
    64 cell lymphoma
    65 chronic lymphocytic leukemia
    66 clinical trials
    67 combination
    68 combination therapy
    69 cyclin D1
    70 deregulation
    71 development
    72 development of inhibitors
    73 early clinical trials
    74 family
    75 family members
    76 family proteins
    77 incurable B-cell lymphoma
    78 inhibitor venetoclax
    79 inhibitors
    80 insights
    81 leukemia
    82 lymphocytic leukemia
    83 lymphoma
    84 mantle cell lymphoma
    85 mechanism
    86 members
    87 microenvironment
    88 myeloid cell leukemia-1
    89 myeloid leukemia
    90 organ microenvironment
    91 outcomes
    92 overexpression
    93 patient outcomes
    94 patients
    95 primary resistance
    96 progress
    97 promising results
    98 protein
    99 rational combination
    100 rational combination therapies
    101 recent progress
    102 resistance
    103 results
    104 role
    105 significant subset
    106 subset
    107 target
    108 therapy
    109 translocation
    110 treatment
    111 trials
    112 upregulation
    113 venetoclax
    114 venetoclax resistance
    115 schema:name Tipping the balance: toward rational combination therapies to overcome venetoclax resistance in mantle cell lymphoma
    116 schema:pagination 2165-2176
    117 schema:productId N67a797b1842d4636a64579b8ec538ab2
    118 Na0895da69bbc4d80b1bdbcf09352399c
    119 Nf52174d880ba4458a89cdcb76d6cabaa
    120 schema:sameAs https://app.dimensions.ai/details/publication/pub.1148806066
    121 https://doi.org/10.1038/s41375-022-01627-9
    122 schema:sdDatePublished 2022-10-01T06:50
    123 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    124 schema:sdPublisher Nda42f6d1b0184a5180c1cf1b821c9e57
    125 schema:url https://doi.org/10.1038/s41375-022-01627-9
    126 sgo:license sg:explorer/license/
    127 sgo:sdDataset articles
    128 rdf:type schema:ScholarlyArticle
    129 N009b8836782141e9b60faf5a5a503e9c schema:volumeNumber 36
    130 rdf:type schema:PublicationVolume
    131 N11d8c0c223ac43afa6fac0c709ac101e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    132 schema:name Tumor Microenvironment
    133 rdf:type schema:DefinedTerm
    134 N29fdcf1fb4594d76a60f8d68c5d2ccc6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    135 schema:name Lymphoma, B-Cell
    136 rdf:type schema:DefinedTerm
    137 N332a0ba1f761446a871e99b27eb1eb88 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    138 schema:name Humans
    139 rdf:type schema:DefinedTerm
    140 N334913203ff4423aba134630aa3fa393 rdf:first sg:person.01324263263.24
    141 rdf:rest Nc7f9917ded5247fd8a7da015f2da20cc
    142 N368ca20fd3794f6693a02ee344c05fde schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    143 schema:name Drug Resistance, Neoplasm
    144 rdf:type schema:DefinedTerm
    145 N5845b7ef0e8e4e97939f7d4faf837737 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    146 schema:name bcl-X Protein
    147 rdf:type schema:DefinedTerm
    148 N67a797b1842d4636a64579b8ec538ab2 schema:name dimensions_id
    149 schema:value pub.1148806066
    150 rdf:type schema:PropertyValue
    151 N6e23007ee6d541c397b0b769c5e8e62b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    152 schema:name Myeloid Cell Leukemia Sequence 1 Protein
    153 rdf:type schema:DefinedTerm
    154 N703a33a2c76f441aaf0ab30d64a26466 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    155 schema:name Antineoplastic Agents
    156 rdf:type schema:DefinedTerm
    157 N75f603c3f1b24743a1209d3b504cfd6b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    158 schema:name Cell Line, Tumor
    159 rdf:type schema:DefinedTerm
    160 N767d659cec51411a8b7f2f6276dbd196 schema:issueNumber 9
    161 rdf:type schema:PublicationIssue
    162 N76f3a49494a74495ae12044ce4683486 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    163 schema:name Adult
    164 rdf:type schema:DefinedTerm
    165 N77163c080ce84af185a6b2681678ce49 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    166 schema:name Proto-Oncogene Proteins c-bcl-2
    167 rdf:type schema:DefinedTerm
    168 N7e79fe65012949f68b02747ea0f9d21c schema:affiliation grid-institutes:grid.16872.3a
    169 schema:familyName Thus
    170 schema:givenName Yvonne J.
    171 rdf:type schema:Person
    172 N7ea667fc86014dc7996a8e33e74b5cd1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    173 schema:name Sulfonamides
    174 rdf:type schema:DefinedTerm
    175 N8ff5a58c5e7a47f794511ba901c83e13 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    176 schema:name Bridged Bicyclo Compounds, Heterocyclic
    177 rdf:type schema:DefinedTerm
    178 N9d932d5e0192425eb5a7a05ea299eb53 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    179 schema:name Lymphoma, Mantle-Cell
    180 rdf:type schema:DefinedTerm
    181 Na0895da69bbc4d80b1bdbcf09352399c schema:name pubmed_id
    182 schema:value 35725771
    183 rdf:type schema:PropertyValue
    184 Nbc928d056e684155aac0aa3fd041338c rdf:first sg:person.0724422422.86
    185 rdf:rest rdf:nil
    186 Nc3feb40582d04ae49e58b9f2f6e9c549 rdf:first N7e79fe65012949f68b02747ea0f9d21c
    187 rdf:rest N334913203ff4423aba134630aa3fa393
    188 Nc7f9917ded5247fd8a7da015f2da20cc rdf:first sg:person.01052273406.90
    189 rdf:rest Nbc928d056e684155aac0aa3fd041338c
    190 Nda42f6d1b0184a5180c1cf1b821c9e57 schema:name Springer Nature - SN SciGraph project
    191 rdf:type schema:Organization
    192 Nf52174d880ba4458a89cdcb76d6cabaa schema:name doi
    193 schema:value 10.1038/s41375-022-01627-9
    194 rdf:type schema:PropertyValue
    195 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    196 schema:name Medical and Health Sciences
    197 rdf:type schema:DefinedTerm
    198 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
    199 schema:name Oncology and Carcinogenesis
    200 rdf:type schema:DefinedTerm
    201 sg:journal.1097065 schema:issn 0887-6924
    202 1476-5551
    203 schema:name Leukemia
    204 schema:publisher Springer Nature
    205 rdf:type schema:Periodical
    206 sg:person.01052273406.90 schema:affiliation grid-institutes:grid.7177.6
    207 schema:familyName Kater
    208 schema:givenName Arnon P.
    209 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01052273406.90
    210 rdf:type schema:Person
    211 sg:person.01324263263.24 schema:affiliation grid-institutes:None
    212 schema:familyName Eldering
    213 schema:givenName Eric
    214 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01324263263.24
    215 rdf:type schema:Person
    216 sg:person.0724422422.86 schema:affiliation grid-institutes:grid.16872.3a
    217 schema:familyName Spaargaren
    218 schema:givenName Marcel
    219 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0724422422.86
    220 rdf:type schema:Person
    221 sg:pub.10.1007/s00262-021-03043-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1140776702
    222 https://doi.org/10.1007/s00262-021-03043-x
    223 rdf:type schema:CreativeWork
    224 sg:pub.10.1007/s10238-013-0268-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1028736156
    225 https://doi.org/10.1007/s10238-013-0268-z
    226 rdf:type schema:CreativeWork
    227 sg:pub.10.1038/cdd.2017.169 schema:sameAs https://app.dimensions.ai/details/publication/pub.1092746764
    228 https://doi.org/10.1038/cdd.2017.169
    229 rdf:type schema:CreativeWork
    230 sg:pub.10.1038/leu.2011.2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028195451
    231 https://doi.org/10.1038/leu.2011.2
    232 rdf:type schema:CreativeWork
    233 sg:pub.10.1038/leu.2011.46 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033286363
    234 https://doi.org/10.1038/leu.2011.46
    235 rdf:type schema:CreativeWork
    236 sg:pub.10.1038/leu.2017.207 schema:sameAs https://app.dimensions.ai/details/publication/pub.1090318815
    237 https://doi.org/10.1038/leu.2017.207
    238 rdf:type schema:CreativeWork
    239 sg:pub.10.1038/leu.2017.32 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074210574
    240 https://doi.org/10.1038/leu.2017.32
    241 rdf:type schema:CreativeWork
    242 sg:pub.10.1038/nrclinonc.2018.8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1100835036
    243 https://doi.org/10.1038/nrclinonc.2018.8
    244 rdf:type schema:CreativeWork
    245 sg:pub.10.1038/onc.2016.155 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007392184
    246 https://doi.org/10.1038/onc.2016.155
    247 rdf:type schema:CreativeWork
    248 sg:pub.10.1038/onc.2016.515 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083804989
    249 https://doi.org/10.1038/onc.2016.515
    250 rdf:type schema:CreativeWork
    251 sg:pub.10.1038/s41375-019-0652-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1123262577
    252 https://doi.org/10.1038/s41375-019-0652-0
    253 rdf:type schema:CreativeWork
    254 sg:pub.10.1038/s41375-020-0934-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1128770760
    255 https://doi.org/10.1038/s41375-020-0934-6
    256 rdf:type schema:CreativeWork
    257 sg:pub.10.1038/s41375-022-01553-w schema:sameAs https://app.dimensions.ai/details/publication/pub.1146886772
    258 https://doi.org/10.1038/s41375-022-01553-w
    259 rdf:type schema:CreativeWork
    260 sg:pub.10.1038/s41416-020-01205-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1133486790
    261 https://doi.org/10.1038/s41416-020-01205-9
    262 rdf:type schema:CreativeWork
    263 sg:pub.10.1038/s41418-020-00692-w schema:sameAs https://app.dimensions.ai/details/publication/pub.1134846320
    264 https://doi.org/10.1038/s41418-020-00692-w
    265 rdf:type schema:CreativeWork
    266 sg:pub.10.1038/s41419-020-03144-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1132250737
    267 https://doi.org/10.1038/s41419-020-03144-y
    268 rdf:type schema:CreativeWork
    269 sg:pub.10.1038/s41420-022-00884-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1145815027
    270 https://doi.org/10.1038/s41420-022-00884-y
    271 rdf:type schema:CreativeWork
    272 sg:pub.10.1038/s41467-018-03170-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1101045812
    273 https://doi.org/10.1038/s41467-018-03170-7
    274 rdf:type schema:CreativeWork
    275 sg:pub.10.1038/s41467-021-26613-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1142539803
    276 https://doi.org/10.1038/s41467-021-26613-0
    277 rdf:type schema:CreativeWork
    278 sg:pub.10.1038/s41568-021-00407-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1141956814
    279 https://doi.org/10.1038/s41568-021-00407-4
    280 rdf:type schema:CreativeWork
    281 sg:pub.10.1038/s41580-020-0255-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1128679372
    282 https://doi.org/10.1038/s41580-020-0255-7
    283 rdf:type schema:CreativeWork
    284 sg:pub.10.1038/s41591-018-0243-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1109946036
    285 https://doi.org/10.1038/s41591-018-0243-z
    286 rdf:type schema:CreativeWork
    287 sg:pub.10.1186/s13045-020-00962-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1130921904
    288 https://doi.org/10.1186/s13045-020-00962-7
    289 rdf:type schema:CreativeWork
    290 sg:pub.10.1186/s13045-021-01188-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1142273846
    291 https://doi.org/10.1186/s13045-021-01188-x
    292 rdf:type schema:CreativeWork
    293 grid-institutes:None schema:alternateName Amsterdam Institute for Infection and Immunity, Cancer Immunology, Amsterdam, The Netherlands
    294 schema:name Amsterdam Institute for Infection and Immunity, Cancer Immunology, Amsterdam, The Netherlands
    295 Cancer Center Amsterdam (CCA), Cancer Biology and Immunology, Target & Therapy Discovery, Amsterdam, The Netherlands
    296 Department of Experimental Immunology, Amsterdam UMC location University of Amsterdam, Amsterdam, The Netherlands
    297 Lymphoma and Myeloma Center Amsterdam (LYMMCARE), Amsterdam, The Netherlands
    298 rdf:type schema:Organization
    299 grid-institutes:grid.16872.3a schema:alternateName Cancer Center Amsterdam (CCA), Cancer Biology and Immunology, Target & Therapy Discovery, Amsterdam, The Netherlands
    300 schema:name Cancer Center Amsterdam (CCA), Cancer Biology and Immunology, Target & Therapy Discovery, Amsterdam, The Netherlands
    301 Department of Pathology, Amsterdam UMC location University of Amsterdam, Amsterdam, The Netherlands
    302 Lymphoma and Myeloma Center Amsterdam (LYMMCARE), Amsterdam, The Netherlands
    303 rdf:type schema:Organization
    304 grid-institutes:grid.7177.6 schema:alternateName Department of Hematology, Amsterdam UMC location University of Amsterdam, Amsterdam, The Netherlands
    305 schema:name Cancer Center Amsterdam (CCA), Cancer Biology and Immunology, Target & Therapy Discovery, Amsterdam, The Netherlands
    306 Department of Hematology, Amsterdam UMC location University of Amsterdam, Amsterdam, The Netherlands
    307 Lymphoma and Myeloma Center Amsterdam (LYMMCARE), Amsterdam, The Netherlands
    308 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...